Compare PUK & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PUK | ZTS |
|---|---|---|
| Founded | 1848 | 1952 |
| Country | Hong Kong | United States |
| Employees | N/A | 14500 |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 29.0B |
| IPO Year | 2001 | 2012 |
| Metric | PUK | ZTS |
|---|---|---|
| Price | $25.24 | $70.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $154.18 |
| AVG Volume (30 Days) | 890.5K | ★ 3.2M |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | 1.68% | ★ 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 3.08 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | N/A | $5.63 |
| Revenue Next Year | $8.92 | $4.77 |
| P/E Ratio | $23.76 | ★ $22.83 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $24.61 | $69.93 |
| 52 Week High | $34.03 | $148.79 |
| Indicator | PUK | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 30.09 | 38.66 |
| Support Level | $24.61 | N/A |
| Resistance Level | $28.44 | $78.20 |
| Average True Range (ATR) | 0.35 | 1.58 |
| MACD | -0.14 | -0.29 |
| Stochastic Oscillator | 7.36 | 23.48 |
Originally established in 1848 as the Prudential Mutual Assurance, Investment, and Loan Association, Prudential has changed a lot since. Set up to sell life insurance and loans to the middle class, the company subsequently diversified into Europe and then North America with the purchase of Jackson National Life around 1985. During its time as owner of Jackson, Prudential focused on building a simple chassis-style product portfolio that allowed customers to choose from a variety of add-ons. The company also became renowned for its focus on building the internal capabilities required to support its strong product offerings, including compelling technology and a large well-trained wholesale salesforce.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.